ReviewScientific reports2026
What are the limits to biomedical research acceleration through general-purpose AI?
Review in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robotic perturbation proteomics and AI agents enable scalable drug mechanism discovery.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although general-purpose artificial intelligence (GPAI) is widely expected to accelerate scientific discovery, its practical limits in biomedicine remain unclear. We assess this potential by developing a framework of GPAI capabilities across the biomedical research lifecycle. Our scoping literature review indicates that current GPAI could deliver a speed increase of around 2x, whereas future GPAI could facilitate strong acceleration of up to 25x for physical tasks and 100x for cognitive tasks. However, achieving these gains may be severely limited by factors such as irreducible biological constraints, research infrastructure, data access, and the need for human oversight. Our expert elicitation with eight senior biomedical researchers revealed skepticism regarding the strong acceleration of tasks such as experiment design and execution. In contrast, strong acceleration of manuscript preparation, review and publication processes was deemed plausible. Notably, all experts identified the assimilation of new tools by the scientific community as a critical bottleneck. Realising the potential of GPAI will therefore require more than technological progress; it demands targeted investment in shared automation infrastructure and systemic reforms to research and publication practices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.